June 2026

India is aiming to achieve pharmaceutical exports worth USD 50 billion by 2030, driven by a strong focus on quality manufacturing, innovation, regulatory excellence, and international collaboration. The vision was highlighted during discussions involving global drug regulators, industry leaders, and policymakers, underscoring India's ambition to strengthen its position as a leading supplier of medicines to the world.

In a major advancement for HIV treatment, Gilead Sciences and Merck have announced positive topline results from two pivotal Phase 3 clinical trials evaluating an investigational once-weekly oral HIV therapy that combines islatravir and lenacapavir. The promising findings bring the healthcare industry one step closer to introducing what could become the world's first long-acting oral HIV treatment taken just once a week.

A groundbreaking European clinical trial has shown that using a common, harmless virus as a biomarker to guide immunosuppressive treatment after kidney transplantation is both safe and effective, paving the way for more personalized transplant care.